Abstract
EDITORIAL article Front. Aging Neurosci., 21 October 2014Sec. Alzheimer's Disease and Related Dementias https://doi.org/10.3389/fnagi.2014.00281
Highlights
When I was invited by Frontiers to serve as Guest Editor of a Research Topic I had no doubts about the topic to address: the clinical use of biomarkers for neurodegenerative disorders
Regarding the usefulness of cerebrospinal fluid levels (CSF) biomarkers in the differential diagnosis of FTLD vs. AD, an interesting review by D Irwin, J Trojanowski, and M Grossman highlight that CSF measurements of Aβ1-42, t-tau, and p-tau differ significantly in FTLD from the abnormal levels seen in AD, and in a subset of both FTLD-tau and FTLD-TDP there are extremely low levels of t-tau of unclear etiology (Irwin et al, 2013)
Researchers for the Alzheimer’s Disease Neuroimaging Initiative (ADNI) evaluated the association of APOE with amyloid deposition, cerebrospinal fluid levels (CSF) of Aβ, tau, and p-tau, brain atrophy, cognition, and cognitive complaints in patients with early-Mild Cognitive Impairment (E-MCI) and cognitively healthy older adults (HC) and found that cortical amyloid deposition and CSF levels of Aβ were significantly associated with APOE ε4 status but not E-MCI diagnosis, with ε4 positive participants showing more amyloid deposition and lower levels of CSF Aβ than ε4 negative participants (Risacher et al, 2013)
Summary
When I was invited by Frontiers to serve as Guest Editor of a Research Topic I had no doubts about the topic to address: the clinical use of biomarkers for neurodegenerative disorders. Following with simple methods for assessing MTA in the clinical setting, researchers from Florida describe the utility of age-specific cut-offs for visual rating of medial temporal atrophy in classifying Alzheimer’s disease, MCI, and cognitively normal elderly subjects (Duara et al, 2013).
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have